Q-omics provides the consensus-scored RNU12-2P profile across patient tissues and cancer cell-line models. RNU12-2P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNU12-2P is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RNU12-2P RNA expression shows 13,578 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight DLBC, KICH, and UVM as cancer lineages where RNU12-2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU12-2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU12-2P survival associations across molecular data types. RNU12-2P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU12-2P RNA expression–survival associations across cancer types. High RNU12-2P expression shows unfavorable associations in DLBC and BLCA, but favorable associations in STAD, LUSC, MESO and READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify DLBC as the clearest survival context for RNU12-2P RNA expression.
This table summarizes RNU12-2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU12-2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU12-2P shows lower tumor expression in LUAD and higher tumor expression in KICH, KIRC, LIHC, BLCA and CHOL. The KICH box plot shows higher RNU12-2P RNA expression in tumor versus normal tissue (log2 FC = +0.523, t-test p = .001).
This table shows molecular features associated with RNU12-2P in patient tissues and cancer cell lines. In patient samples, RNU12-2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
